Table 1 The clinical characteristics of Down syndrome (DS) neonates in this study. In the “no blasts detected” column are the patients who were screened and in whom no blasts were detected using immunophenotyping and morphology, in the “blasts detected” column only those in which blasts were detected and who were classified as TAM.
No blasts detected | Blasts detected | |
|---|---|---|
Total number of patients | 323 | 45 |
Sex (male) | 177/323 (55%) | 19/36 (53%) |
Median pregnancy duration (weeks, range) | 38 (31–42) | 37.5 (33–40) |
Died in the neonatal period | 3/108 (2.8%) | 6/21 (29%) |
First postnatal complete blood count | ||
Hemoglobin (mmol/L, median, p25–p75) | 12.7 (10.7–13.9) | 11.0 (9.4–12.4) |
White blood cell count (median, *10 9/L, p25–p75) | 15.1 (10.7–21) | 20.1 (12.4–37.3) |
Thrombocyte count (median, *10 9/L, p25–p75) | 137 (85–201) | 121 (40–201) |
Blasts by morphology (%, median, p25–75) | 0 | 10 (4.5–28%) |
Hydrops fetalis | 0 | 3/14 (21%) |
Pleural effusion | 2/170 (1.2%) | 1/14 (7%) |
Pericardial effusion | 2/168 (1.2%) | 2/14(14%) |
Ascites | 0 | 3/14 (21%) |
ML DS (during follow-up) | 2/323 (0.6%) | 6/45 (13%) |
DS ALL (during follow-up) | 3/323 (0.9%) | 1/45 (2.2%) |
